IntelePeer is a provider of cloud-based communication solutions, focusing on enhancing business communications through its CPaaS-based platform. The company offers a range of services, including enterprise voice, SIP trunking, and cloud contact center solutions. By integrating AI and analytics, IntelePeer's platform enables businesses to improve customer interactions and drive revenue growth. Its omnichannel approach allows for seamless communication across various channels, facilitating better decision-making and customer satisfaction. The platform is designed to work effortlessly with existing business systems, making it a versatile choice for enterprises looking to enhance their communication capabilities.
Direct Flow Medical is a medical device company specializing in the development of transcatheter aortic tissue valve prostheses aimed at treating cardiac valve insufficiency. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, the company addresses a significant healthcare need, as only about 150,000 of these cases receive surgical treatment annually. The company's innovative technologies focus on improving patient outcomes and minimizing complications associated with heart valve replacement. By offering repeated assessments of hemodynamic performance prior to final implantation, Direct Flow Medical enables heart surgeons to perform valve replacements through less invasive procedures, thereby enhancing the safety and effectiveness of cardiac interventions.
TransCorp Spine manufactures medical devices and procedures to restore spinal function and preserve healthy tissue. Its product includes SpinePort, a MIS access system. David Lowry, Des O'Farrell, and Scott Tuinstra founded TransCorp Spine in 2008. It has its headquarters in Byron Center in Michigan.
Sonoma Orthopedic Products specializes in the design, development, and delivery of proprietary orthopedic implants aimed at assisting physicians in the treatment of problematic fractures. The company's innovative WaviBody technology platform facilitates quick and minimally invasive surgical solutions, catering to the needs of active patients. By focusing on advanced orthopedic solutions, Sonoma Orthopedic Products aims to enhance patient recovery and overall quality of care.
Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.
Direct Flow Medical is a medical device company specializing in the development of transcatheter aortic tissue valve prostheses aimed at treating cardiac valve insufficiency. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, the company addresses a significant healthcare need, as only about 150,000 of these cases receive surgical treatment annually. The company's innovative technologies focus on improving patient outcomes and minimizing complications associated with heart valve replacement. By offering repeated assessments of hemodynamic performance prior to final implantation, Direct Flow Medical enables heart surgeons to perform valve replacements through less invasive procedures, thereby enhancing the safety and effectiveness of cardiac interventions.
ValenTx, Inc. is a medical device company based in Maple Grove, Minnesota, established in 2002. It specializes in developing minimally invasive therapy solutions aimed at treating obesity and its related metabolic disorders, including type-2 diabetes and hypertension. One of its key innovations is an endoluminal bypass therapy that replicates the anatomical changes associated with the Roux-en-Y gastric bypass procedure using an adjustable, removable, and replaceable device. ValenTx's focus is on providing effective treatment options for individuals struggling with morbid obesity and related health issues.
Lycera Corp. is a biopharmaceutical company focused on developing small molecule immunomodulatory medicines aimed at treating autoimmune diseases and cancer. Founded in 2006 and based in Ann Arbor, Michigan, with additional offices in New York and Pennsylvania, Lycera is in the preclinical stage and specializes in first-in-class therapies. Its lead drug candidate, LYC-55716, utilizes multiple anti-tumor mechanisms to modulate gene expression, enhancing immune cell function while reducing immunosuppressive effects. The company also develops ATPase modulators for conditions such as rheumatoid arthritis, lupus erythematosus, psoriasis, and inflammatory bowel disease. Lycera's innovative approach seeks to provide oral efficacy without the adverse effects associated with traditional antiproliferative and immunosuppressive treatments.
Vontoo is a provider of automated voice messaging tools that focuses on enhancing one-to-one marketing communication through the use of human voice. The company offers a web-based application that enables organizations to create, send, and track personalized voice messages tailored to the interests of individual recipients. Vontoo's platform allows clients to initiate automated calls ranging from one to millions, facilitating improved customer relationships, faster cash collection, and cost reduction. Headquartered in Indianapolis, Vontoo operates privately and is supported by various funding sources, including private investors and a venture capital firm.
Perfinity Biosciences, Inc. specializes in developing tools for protein sample preparation. The company's product portfolio includes a range of consumable kits and automated instrument solutions designed to enhance reproducibility and speed in testing. Key offerings encompass immobilized enzymes, affinity reagents, optimized buffers, and software. Notable products include Soluble Smart Digest, a stable trypsin for efficient digestions; Mag Beads tailored for proteomics; QuicPrep, which combines immunoaffinity and trypsin digestion in a single tube; and Flash Digest, an immobilized trypsin reactor for rapid processing. Additionally, Perfinity provides a multi-column Workstation to automate protein separations and mass spectrometry sample preparation. Founded in 2004 and based in West Lafayette, Indiana, the company aims to simplify workflows for a variety of applications, including solid tissues and gels. Perfinity was previously known as QuadraSpec, Inc. before rebranding in March 2010.
HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.
Elemé Medical, Inc. is a venture backed aesthetics company dedicated to providing market-leading technology in all areas of body shaping. The newly launched SmoothShapes® XV will revolutionize how cellulite is treated and introduce exciting new protocols for pre and post liposuction care. With 50% more laser power, SmoothSpeed™ audible & visual treatment guidance and a portable, sleek console design, SmoothShapes XV is an ideal way to add non-invasive body shaping to a practice. SmoothShapes XV is the newest product launched by the Company and joins the original SmoothShapes launched in 2008, both products are a CE Marked, FDA-cleared medical devices for the temporary reduction in the appearance of cellulite. Both SmoothShapes systems are based on the company's proprietary Photomology® platform – a process that treats cellulite and subcutaneous fat by combining dynamic light and laser energy along with mechanical manipulation (vacuum and massage). The system addresses the physical manifestations of cellulite and its underlying causes providing long lasting results that patients can see and feel. Targets include plastic surgeons, aesthetic dermatologists, medical spas and other aesthetic physicians. According to Global Body Shaping Market Analysis, body shaping is one of the top growth areas in the Aesthetics market with 19% growth through the year 2012. The global aesthetics market is projected to grow from $5.0 billion in 2008 to $8.1 billion by 2011.
Alure Medical
Series A in 2008
Alure Medical focuses on the development and commercialization of percutaneous soft tissue lift devices and delivery systems for plastic surgery utilizing patent-pending technologies.
Nanosolar, Inc. is a manufacturer of solar electricity cells and panels, specializing in cost-efficient solar energy solutions. Founded in 2001 and headquartered in San Jose, California, the company also has manufacturing facilities in Berlin, Germany. Nanosolar utilizes a proprietary printing process to produce CIGS (Copper, Indium, Gallium, Selenium) solar cells and lightweight solar-electric cell foils, known as SolarPly, which can be customized to various sizes. This innovative approach minimizes reliance on expensive vacuum deposition equipment, allowing the company to leverage industrial printing techniques for high-speed production. Nanosolar's product line includes utility panels designed for large-scale power plants, making it a significant player in the solar energy sector.
IntelePeer is a provider of cloud-based communication solutions, focusing on enhancing business communications through its CPaaS-based platform. The company offers a range of services, including enterprise voice, SIP trunking, and cloud contact center solutions. By integrating AI and analytics, IntelePeer's platform enables businesses to improve customer interactions and drive revenue growth. Its omnichannel approach allows for seamless communication across various channels, facilitating better decision-making and customer satisfaction. The platform is designed to work effortlessly with existing business systems, making it a versatile choice for enterprises looking to enhance their communication capabilities.
Greenplum, Inc. is a data warehousing company that specializes in developing database software designed for business intelligence and data warehousing applications. The company's flagship product, Greenplum Database, is tailored to handle multi-terabyte data warehousing requirements, making it suitable for large-scale data operations. Additionally, Greenplum Network serves as a customer and partner portal, providing instant download access to its database products. The company primarily targets clients in the telecommunications and banking sectors, addressing their specific data management and analytics needs.
Direct Flow Medical is a medical device company specializing in the development of transcatheter aortic tissue valve prostheses aimed at treating cardiac valve insufficiency. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, the company addresses a significant healthcare need, as only about 150,000 of these cases receive surgical treatment annually. The company's innovative technologies focus on improving patient outcomes and minimizing complications associated with heart valve replacement. By offering repeated assessments of hemodynamic performance prior to final implantation, Direct Flow Medical enables heart surgeons to perform valve replacements through less invasive procedures, thereby enhancing the safety and effectiveness of cardiac interventions.
RockeTalk was founded with a vision of enabling all people to more easily express themselves and communicate with their friends, family and new acquaintances, as well as capture, share, and discover their content…all over their mobile phones. RockeTalk has developed and launched a social media platform and mobile phone client applications that provide a variety of fast, easy-to-use multimedia services. Users can create any combination of text, voice, photo, and video messages, share with any contacts, join communities and chat with individuals and groups, and access a variety of entertainment and content. RockeTalk makes communication between individuals and groups easy and rich, and facilitates a new form of self-expression that informs, entertains and connects people through the media they create.
BioSET, Inc., founded in 2001 and based in Rockville, Maryland, specializes in the research and development of synthetic bioactive peptides for medical applications. The company focuses on creating proprietary therapeutic peptides and implantable devices designed to enhance bone and soft tissue repair, particularly in orthobiologics. Its flagship product, Amplex, is an implantable device that combines a peptide with a synthetic ceramic scaffold, serving as a surgical bone graft implant for various spinal and orthopedic surgeries, including lumbar degenerative disc disease and foot and ankle fusion procedures. Additionally, BioSET develops products for sports medicine and offers peptide signaling molecules along with diverse scaffold biomaterials to support musculoskeletal applications, including trauma and fracture repair. As of February 2015, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.
Sonoma Orthopedic Products specializes in the design, development, and delivery of proprietary orthopedic implants aimed at assisting physicians in the treatment of problematic fractures. The company's innovative WaviBody technology platform facilitates quick and minimally invasive surgical solutions, catering to the needs of active patients. By focusing on advanced orthopedic solutions, Sonoma Orthopedic Products aims to enhance patient recovery and overall quality of care.
Sonoma Orthopedic Products specializes in the design, development, and delivery of proprietary orthopedic implants aimed at assisting physicians in the treatment of problematic fractures. The company's innovative WaviBody technology platform facilitates quick and minimally invasive surgical solutions, catering to the needs of active patients. By focusing on advanced orthopedic solutions, Sonoma Orthopedic Products aims to enhance patient recovery and overall quality of care.
Arxan Technologies, Inc. specializes in application protection solutions designed to secure software across various platforms, including mobile devices, desktops, servers, and IoT systems. The company offers a range of products, such as GuardIT, which safeguards managed, interpreted, and native code, and EnsureIT, which ensures protection without disrupting the software development lifecycle or performance. Their TransformIT technology employs white box cryptography, while Arxan for Web focuses on defending against server-side attacks and credential theft. Additionally, Arxan provides professional services, including risk assessment and protection design, alongside training and consultation. The company caters to a diverse clientele, including Fortune 500 organizations in sectors such as financial services, healthcare, gaming, and automotive. Founded in 2001 and headquartered in San Francisco, Arxan has established strategic partnerships with firms like IBM and Cigital, enhancing its position as a leader in application security. With over one billion application instances protected, Arxan Technologies offers robust, patented security capabilities that address the evolving threats facing modern applications.
Greenplum, Inc. is a data warehousing company that specializes in developing database software designed for business intelligence and data warehousing applications. The company's flagship product, Greenplum Database, is tailored to handle multi-terabyte data warehousing requirements, making it suitable for large-scale data operations. Additionally, Greenplum Network serves as a customer and partner portal, providing instant download access to its database products. The company primarily targets clients in the telecommunications and banking sectors, addressing their specific data management and analytics needs.
Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.
Lycera Corp. is a biopharmaceutical company focused on developing small molecule immunomodulatory medicines aimed at treating autoimmune diseases and cancer. Founded in 2006 and based in Ann Arbor, Michigan, with additional offices in New York and Pennsylvania, Lycera is in the preclinical stage and specializes in first-in-class therapies. Its lead drug candidate, LYC-55716, utilizes multiple anti-tumor mechanisms to modulate gene expression, enhancing immune cell function while reducing immunosuppressive effects. The company also develops ATPase modulators for conditions such as rheumatoid arthritis, lupus erythematosus, psoriasis, and inflammatory bowel disease. Lycera's innovative approach seeks to provide oral efficacy without the adverse effects associated with traditional antiproliferative and immunosuppressive treatments.
ValenTx, Inc. is a medical device company based in Maple Grove, Minnesota, established in 2002. It specializes in developing minimally invasive therapy solutions aimed at treating obesity and its related metabolic disorders, including type-2 diabetes and hypertension. One of its key innovations is an endoluminal bypass therapy that replicates the anatomical changes associated with the Roux-en-Y gastric bypass procedure using an adjustable, removable, and replaceable device. ValenTx's focus is on providing effective treatment options for individuals struggling with morbid obesity and related health issues.
Greenplum, Inc. is a data warehousing company that specializes in developing database software designed for business intelligence and data warehousing applications. The company's flagship product, Greenplum Database, is tailored to handle multi-terabyte data warehousing requirements, making it suitable for large-scale data operations. Additionally, Greenplum Network serves as a customer and partner portal, providing instant download access to its database products. The company primarily targets clients in the telecommunications and banking sectors, addressing their specific data management and analytics needs.
Direct Flow Medical is a medical device company specializing in the development of transcatheter aortic tissue valve prostheses aimed at treating cardiac valve insufficiency. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, the company addresses a significant healthcare need, as only about 150,000 of these cases receive surgical treatment annually. The company's innovative technologies focus on improving patient outcomes and minimizing complications associated with heart valve replacement. By offering repeated assessments of hemodynamic performance prior to final implantation, Direct Flow Medical enables heart surgeons to perform valve replacements through less invasive procedures, thereby enhancing the safety and effectiveness of cardiac interventions.
Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.
BioSET, Inc., founded in 2001 and based in Rockville, Maryland, specializes in the research and development of synthetic bioactive peptides for medical applications. The company focuses on creating proprietary therapeutic peptides and implantable devices designed to enhance bone and soft tissue repair, particularly in orthobiologics. Its flagship product, Amplex, is an implantable device that combines a peptide with a synthetic ceramic scaffold, serving as a surgical bone graft implant for various spinal and orthopedic surgeries, including lumbar degenerative disc disease and foot and ankle fusion procedures. Additionally, BioSET develops products for sports medicine and offers peptide signaling molecules along with diverse scaffold biomaterials to support musculoskeletal applications, including trauma and fracture repair. As of February 2015, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.
Oxand is an international consulting and solutions provider with proven capabilities, knowledge and tools for capital intensive assets. As an independent company, they deliver risk-informed decision support information that improves returns across the life cycle of their clients’ assets. Their worldwide clients are investors, owners, contractors and managers in Energy (Nuclear, Oil & Gas, Renewables), Transport (Railways, Roads & Waterways) and Public/Private Properties (Public Infrastructures, Private & Industrial assets). Enhancing their clients’ reputations by supporting better decisions, with more than 1,150 billion Euros worth of analysed assets, they have experience that includes optimising the life cycle decisions and reducing costs by 10 to 30%; making possible life extension versus renewals; and reducing costly delays of large projects. Their solutions, supported by their Simeo™ technologies and data libraries, are fully compliant with best standards (as ISO 55000, ISO 31000, ISO 15288, NEC3…). They deliver tailored consultancy, training and IT solutions.
HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.
Xtera Communications, Inc. was a provider of optical transport solutions, specializing in Raman amplification enabled systems for both terrestrial and submarine networks. Founded in 1998 and headquartered in Allen, Texas, the company served telecommunications service providers, content service providers, enterprises, and government entities globally. Xtera offered a range of products, including un-repeatered and repeatered systems, designed to enhance network reach and capacity. The company focused on creating customized solutions, whether through complete turnkey systems, open architecture designs, or specific product offerings. Xtera's strategic growth included the acquisition of AscenVision, which expanded its product portfolio beyond optical solutions. However, Xtera entered Chapter 11 bankruptcy in November 2016, and its liquidation process began in February 2017, marking the end of its operations.
Arxan Technologies, Inc. specializes in application protection solutions designed to secure software across various platforms, including mobile devices, desktops, servers, and IoT systems. The company offers a range of products, such as GuardIT, which safeguards managed, interpreted, and native code, and EnsureIT, which ensures protection without disrupting the software development lifecycle or performance. Their TransformIT technology employs white box cryptography, while Arxan for Web focuses on defending against server-side attacks and credential theft. Additionally, Arxan provides professional services, including risk assessment and protection design, alongside training and consultation. The company caters to a diverse clientele, including Fortune 500 organizations in sectors such as financial services, healthcare, gaming, and automotive. Founded in 2001 and headquartered in San Francisco, Arxan has established strategic partnerships with firms like IBM and Cigital, enhancing its position as a leader in application security. With over one billion application instances protected, Arxan Technologies offers robust, patented security capabilities that address the evolving threats facing modern applications.
HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.
Virtual Silicon Technology is a provider of SIP solutions to manufacturers and designers of system-on-chip semiconductors.
MetaMatrix is an U.S.-based technology company that created the first true Enterprise Information Integration (EII) software product.
IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.
Ican Inc., is a provider of Internet-based information and tools for health professionals.
Ican provides Internet-based information and tools for health professionals.
Alfalight specializes in the design and manufacture of high-power diode lasers tailored for industrial, defense, and telecommunications applications. The company utilizes advanced aluminum-free active region (ALFA) laser structures, which contribute to the production of laser diodes that are noted for their high reliability and efficiency. Alfalight's product range includes short-wave infrared, near-infrared, and visible lasers, alongside various laser and electro-optical systems. These innovations position Alfalight as a key player in meeting the demands of both security and telecommunication sectors.
Centromine
Venture Round in 1999
Centromine offers a browser-based, internet-accessed, enterprise-wide software applications and services for the health care market. Its applications allow behavioral health care programs and providers to manage the delivery and associated quality and cost of services completely over the internet.
IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.
Pixelworks, Inc. specializes in developing and marketing semiconductor and software solutions for high-end display applications. The company offers a range of video display processor products, including image processor integrated circuits (ICs), video co-processor ICs, and transcoder ICs, which enhance video performance and facilitate the conversion of bitrates, resolutions, and codecs. Its solutions are utilized in various devices such as smartphones, tablets, projectors, and digital signage, ensuring high-quality viewing experiences across multiple formats. Founded in 1997 and headquartered in San Jose, California, Pixelworks holds an extensive intellectual property portfolio with numerous patents related to digital image data display. The company distributes its products through a direct sales force and a network of distributors and representatives globally, catering to markets including mobile, home, enterprise, and cinema.
IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.